Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Inclusion Criteria

• •Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer
• •* Stage IIB, IIC, III, or IV disease
• •* Optimal or suboptimal residual disease after debulking surgery within the past 12 weeks
• •* Appropriate tissue for histologic evaluation available
• •The following histologic epithelial cell types are eligible:
• •* Serous adenocarcinoma
• •* Endometrioid adenocarcinoma
• •* Mucinous adenocarcinoma
• •* Undifferentiated carcinoma
• •* Clear cell adenocarcinoma
• •* Mixed epithelial carcinoma
• •* Transitional cell carcinoma
• •* Malignant Brenner tumor
• •* Adenocarcinoma not otherwise specified
• •* Carcinosarcoma
• •No ovarian epithelial carcinoma of low malignant potential (borderline carcinomas)
• •No synchronous primary endometrial cancer or a history of primary endometrial cancer unless all of the following conditions are met:
• •* Stage ≤ IB disease
• •* No more than superficial myometrial invasion, without vascular or lymphatic invasion
• •* No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesion
• •GOG performance status 0-2
• •ANC ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Bilirubin ≤ 1.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •SGOT ≤ 2.5 times ULN
• •Audiograms required after study chemotherapy courses 3 and 6 for patients with hearing loss, or who are experiencing tinnitus during study therapy
• •Negative pregnancy test
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •None of the following:
• •* Septicemia
• •* Severe infection requiring parenteral antibiotics
• •* Malnutrition requiring parenteral hyperalimentation
• •* Acute hepatitis
• •* Any other major medical conditions expected to interfere with completion of protocol therapy
• •No active bleeding
• •No circumstances that would prohibit completion of study therapy or required follow-up
• •No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E)
• •No other invasive malignancies, except for nonmelanoma skin cancer or other specific malignancies within the past 5 years, or whose previous cancer treatment contraindicates this protocol therapy
• •No unstable angina or myocardial infarction within the past 6 months
• •* Abnormal cardiac conduction (e.g., bundle branch block or heart block) that has been stable for the past 6 months allowed
• •No prior targeted therapy for the management of ovarian epithelial or primary peritoneal cavity cancer including, but not limited to, the following:
• •* Vaccines
• •* Antibodies
• •* Tyrosine kinase inhibitors
• •No prior chemotherapy
• •No prior radiotherapy
• •No prior hormonal therapy for the management of epithelial ovarian or primary peritoneal cavity cancer